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Accuracy of the tuberculosis point‑of‑care
Alere determine lipoarabinomannan antigen
diagnostic test using α‑mannosidase treated
and untreated urine in a cohort of people living
with HIV in Guatemala
Juan Ignacio García1,2*† , Johanna Meléndez3†, Rosa Álvarez4†, Carlos Mejía‑Chew5, Holden V. Kelley2,
Sabeen Sidiki2, Alejandra Castillo6,7, Claudia Mazariegos6,7, Cesar López‑Téllez6,7, Diana Forno8, Nancy Ayala9,
Joan‑Miquel Balada‑Llasat10, Carlos Rodolfo Mejía‑Villatoro3, Shu‑Hua Wang11, Jordi B. Torrelles2*
and Janet Ikeda6,7*

Abstract
Background: Improved point-of-care diagnostic tests for tuberculosis (TB) in severe immune suppressed people
living with HIV (PLWH) are needed to decrease morbidity and mortality outcomes. The aim of the study is to evalu‑
ate the performance of the lipoarabinomannan antigen test (LAM-test) with and without α-mannosidase pre-treated
urine in a cohort of PLWH in primary care clinics in Guatemala. We further determined TB incidence, and mortality
rates and its risk factors in PLWH with TB symptoms.
Methods: Prospective longitudinal study of PLWH with TB symptoms. Urine samples were collected at 2 HIV sites to
test the sensitivity of the LAM-test in urine with and without α-mannosidase pre-treatment. A composite reference
standard of either a positive Mycobacterium tuberculosis complex culture and/or G
 eneXpert® MTB/RIF (Xpert, Cepheid,
Sunnyvale, CA, USA) results was used in the LAM-test diagnostic accuracy studies. Cox proportional hazards regression
was used to study mortality predictors.
Results: The overall sensitivity of the LAM-test was of 56.1% with 95% CI of (43.3–68.3). There were no differences
in the LAM-test sensitivity neither by hospital nor by CD4 T cell values. LAM-test sensitivity in PLWH with < 200 CD4 T
cells/µl was of 62.2% (95% CI 46.5–76.2). There were no significant differences in sensitivity when comparing LAM-test
results obtained from untreated vs. α-mannosidase treated urine [55.2% (95% CI 42.6–67.4) vs. 56.9% (95% CI 44–69.2),
respectively]. TB incidence in our cohort was of 21.4/100 person years (PYs) (95% CI 16.6–27.6), and mortality rate was
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of 11.1/100 PYs (95% CI 8.2–15.0). Importantly, PLWH with a positive LAM-test result had an adjusted hazard ratio (aHR)
of death of 1.98 (1.0–3.8) with a significant p value of 0.044 when compared to PLWH with a negative LAM-test result.
Conclusions: In this study, α-mannosidase treatment of urine did not significantly increase the LAM-test perfor‑
mance, however; this needs to be further evaluated in a large-scale study due to our study limitations. Importantly,
high rates of TB incidence and mortality were found, and a positive LAM-test result predicted mortality in PLWH with
TB clinical symptoms.
Keywords: Tuberculosis, Lipoarabinomannan antigen, Point-of-care diagnosis, HIV, Urine, Mycobacterium tuberculosis

Introduction
Mycobacterium tuberculosis culture is the reference
standard for tuberculosis (TB) diagnosis worldwide;
however, it is not routinely used in low-income countries
due to its high cost, lack of laboratory capacity and long
turnaround time (2 to 6 weeks). Consequently, in high TB
burden settings with limited resources, sputum smear
microscopy detecting acid fast bacilli (AFB) remains the
main laboratory TB diagnostic test for the majority of
rural health care centers [1, 2].
In 2010, the World Health Organization (WHO)
endorsed the G
 eneXpert® MTB/RIF assay (Xpert, Cepheid, Sunnyvale, CA, USA) as the initial diagnostic test
for people living with HIV (PLWH) with presumptive
pulmonary TB (PTB). The Xpert rapidly (2-h) detects
99% of smear-positive and 70% of smear-negative in
people with PTB [3]. Conversely, severely immune suppressed PLWH with presumptive extrapulmonary or
disseminated TB fail in getting a positive Xpert result,
mainly because they are too ill to produce a quality sputum sample, or their sputum contains very few AFB. For
these individuals, currently the Xpert is unlikely to be
useful and thus, the need of alternative TB diagnostic
tests with increased sensitivity to provide early treatment
and care and reduce mortality in PLWH having extrapulmonary or disseminated TB [4].
Lipoarabinomannan (LAM) is a M. tuberculosis cell
envelope lipoglycan that is being explored as a biomarker
for active TB disease. LAM is a heterogeneous, stable,
immunogenic, and virulent factor thought to be released
into the milieu by active or degrading bacilli [5, 6]. M.
tuberculosis LAM is a tripartite structure composed of
a lipid moiety [glycosyl-phosphatidyl-myo-inositol (GPI)
anchor] with different degree of acylation by different
fatty acids. It also contains D-Mannan and D-Arabinan
domains, and in its non-reducing end has mannose-caps,
defining the typical M. tuberculosis complex ManLAM
[7]. LAM heterogeneity resides at the different degrees
of acylation in its GPI-anchor, mannose-capping, and
branching in both D-Mannan and D-Arabinan domains.
Once released into the bloodstream, LAM is filtered
by the kidneys and detected in the urine [8, 9]. In this
context, Alere Determine TB LAM Ag test (LAM-test)

performed in urine has great expectations for its potential to improve the diagnosis of TB in PLWH with low
CD4 cell counts, and who are at greatest risk of death if
TB remains undiagnosed. There are several studies that
performed LAM-test TB diagnosis accuracy assays in
TB high burden areas [10]. Lawn et al. described that
among PLWH eligible to start antiretroviral treatment
in South Africa, the urine LAM-test has highest sensitivity for the detection of culture positive PTB at low
CD4 cell counts. However, in this study, the estimates
precision of the LAM-test was poor due to wide and
overlapping confidence intervals, with 66.7% sensitivity (95% CI 41.0–86.7) in PLWH with CD4 < 50 cells/
µl, 51.7% (32.5–70.6) at CD4 < 100 cells/µl, and 39.0%
(26.5–52.6) at CD4 < 200 cells/µl [11]. Notably, this
study identified a subgroup of PLWH with TB disease
with poor prognosis and high mortality. Conversely,
Peter et al. observed a higher sensitivity in those with
CD4 < 200 cells/ml (72%, 95% CI 61–80) compared to
CD4 > 200 cells/ml (54%, 95% CI 36–71) [12]. This variability observed is thought to be related to: (i) the failure to contain the infection in the lungs resulting in
disseminated TB with renal involvement and presence
of LAM in urine; (ii) dysfunctional humoral immunity
results in abundant free LAM, which can pass into
the urine through the glomerular filtration, whereas
immune complexes of antibody-bound LAM do not;
(iii) dysfunctional cellular immunity drives host susceptibility to less virulent mycobacteria, which may
have different LAM structures; and/or iv) different geographically distributed strains presenting diverse LAM
structures [13].
To date, no studies have evaluated the LAM-test in
Central America. Herein, we focused on the LAM-test
to address its efficacy in detecting M. tuberculosis in a
cohort of PLWH with TB symptoms in Guatemala. We
also determined if a 30 min α-mannosidase pre-treatment of urine using an enzyme that removes the mannose caps of LAM could improve the sensitivity of the
LAM-test as we have shown in the laboratory settings
[14], and further correlated LAM-test results with TB
incidence, mortality rates, and risk factors in our cohort
of PLWH.
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Materials and methods
Ethic committee

The Ethical Review Committee of the Guatemalan Ministry of Health and Social Welfare approved this study protocol with approval number 45-2014. The Institutional
Review Board at The Ohio State University approved this
study protocol with approval number 2013H0251.
Study design

A prospective cohort study of PLWH recruited from
April 2015 to December 2017. Follow up period ended on
December 31st, 2017. All PLWH with clinical (4-Symptoms WHO active TB screening: i.e., cough, weight loss,
night sweats, and fever [15]) and/or radiological abnormalities concerning for PTB or extrapulmonary TB were
offered to participate in this study. A total of 361 PLWH
with TB symptoms were enrolled and followed up during
the study period. After TB/HIV counselling, participants
provided their written inform consent and were recruited
following our human subjects IRB approved protocols.
To estimate TB incidence and death rates, person-years
of follow up (PYs) were calculated using participants’
entry date to the study and censoring occurred at either
TB date, lost to follow up, death, or study recruitment
ending date (December 31st 2017). The last study participant was recruited in December 6th 2017.
Study settings

This study took place in two UAI clinics (‘Unidad de
Atención Integral’) in Guatemala. UAI clinics function as a One Stop TB/HIV service delivery model [16]
for integral management of the TB/HIV syndemic [17].
The ‘Dr. Isaac Cohen Alcahé’ UAI (henceforth UAI 1) is
located within the regional, respiratory infection and TB
Specialty Hospital ‘Rodolfo Robles’ in the rural highland
region of Quetzaltenango, Guatemala. It attends mostly
to indigenous individuals, who come from distant communities in western Guatemala and the southern part
of Chiapas, Mexico. These communities have limited
resources and low educational levels, and an increasing
number of lesbian, gay, bisexual, and transgender (LGBT)
populations [18, 19]. The other UAI involved in this study
is the ‘Dr. Carlos Rodolfo Mejía-Villatoro” Clinic (henceforth UAI 2) the largest HIV clinic in Guatemala, located
within the Roosevelt Hospital in Guatemala City, one of
the two national reference hospitals in Guatemala. UAI
2 attends individuals that have been referred from other
smaller UAIs and from patients from all over the country. Participants in this study were both, ambulatory
and hospitalized patients admitted from emergency services, external consultations within hospitals and waiting rooms in UAIs. Site 1 includes UAI 1 and Hospital
Rodolfo Robles and Site 2 includes UAI 2 and Roosevelt
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Hospital. Enrolled PLWH initiated anti-TB treatment in
accordance with the National TB Control Program of
Guatemala guidelines [20]; urine samples were collected
from all enrolled subjects prior they started their anti-TB
treatment.
TB diagnosis

All subjects were recruited from inpatient and outpatient
setting and screened for WHO-defined four TB clinical
symptoms [21]. Rapid antibody HIV tests were offered to
all individuals with TB clinical symptoms. Positive rapid
tests were confirmed with fourth generation ELISA/P24
tests. The study team (infectious disease specialist, a
nurse, and a microbiologist) explained risks and benefits
of participating in the study and obtained informed consent. Potential participants were screened for inclusion
criteria.
The Gold standard for TB diagnosis was a composite reference standard defined as either a M. tuberculosis positive culture or a positive Xpert result. Samples
obtained included smear sputum for acid-fast bacilli
(AFB) and Xpert, and urine for Xpert and LAM-test. In
some instances, abscesses, biopsies or other body fluids
were taken. Both UAI 1 and UAI 2 followed the combined antiretroviral therapy (cART) protocol for early
cART initiation (2 weeks after the onset of anti-TB treatment [20]). Ambulatory PLWH were referred to the
health center nearest to their residence to initiate anti-TB
direct observed treatment (DOT).
Laboratory procedures

For mycobacteria culture, clinical specimens (sputum,
cerebrospinal fluid, pleural fluid, biopsy lysates) were
first decontaminated using the BD BBL MycoPrep™ system. Once decontaminated, 5 drops (50 μL/drop) of the
decontaminated sample were added into two tubes with
Löwenstein-Jensen (LJ) medium and in UAI 2, 500 μL
were added into the BD BACTEC™ MGIT (automated
liquid mycobacterial growth indicator tube) system for
mycobacteria growth detection. LJ tubes were incubated
at 37 °C and taken out for manual reading twice a week
for 8 weeks. All solid (LJ) and liquid (MGIT) cultures
suggestive of M. tuberculosis growth were further tested
with the SD BIOLINE TB Ag MPT64 immunochromatographic test to confirm M. tuberculosis complex strains.
MPT64 test negative isolates were verified later as possible nontuberculous mycobacteria (NTM). The final
identification of all M. tuberculosis complex strains was
confirmed using HAIN LifeScience GenoType Mycobacterium CM and GenoType Mycobacterium AS identification kits. Drug susceptibility of the M. tuberculosis
confirmed strains was performed using the HAIN (LifeScience GenoType MTBDRplus and GenoType MTBDRsl)
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kits. In UAI 1, all solid (LJ) cultures suggestive of M.
tuberculosis growth were further tested for drug susceptibility at the National Reference Laboratory.
The Xpert test was performed from decontaminated
clinical specimens. Following the manufacturer’s instructions, 1 ml of the specimen was mixed with 2 ml of the
kit reagent. The mixture was pipetted into the cartridge
and inserted into the Xpert instrument for processing.
All urine samples were collected at recruitment, and
stored at − 20 °C before use. For each individual, the
same urine sample was used to perform the LAM-test in
both, untreated and α-mannosidase treated urine. Briefly,
for the LAM-test, 60 μL of urine were directly pipetted
on the LAM-test strip. After 25 min, results were read
and interpreted following the manufacturer’s instructions [3]. For the α-mannosidase treatment of urine,
a urine-sodium bicarbonate mixture (1:1, v/v, 100 μL
final volume) was treated with 0.1 IU of α-mannosidase
(Sigma-Aldrich, San Louis, MO) and incubated at 37 °C
for 15 min. The LAM-test was performed using 60 μL
of this mixture according to the manufacturer’s instructions. A LAM-test was read as positive using an intensity
band grade scale from 1 to 4. Two independent clinicians
agreed on readings for both, LAM-test and LAM-test
after α-mannosidase treatment of urine; however, LAMtest band intensity readings were not recorded.
Study definitions

Combinational antiretroviral therapy (cART) regimens
are defined in Table 1. Diabetic PLWH were defined as
those with percentage of haemoglobin A1C (% Hba1c)
measurements above 6.1 [22]. Body mass index (BMI)
was re-categorized as binary defining ≥ 17 kg/m2
and < 17 kg/m2. WHO HIV stage was binary defined as 1
or 2 and 3 or 4.
Statistical analysis

In the descriptive analysis, proportions were compared
using the Chi square test. U Mann–Whitney was used to
compare medians in different groups as appropriate. The
significance for all comparison tests was set at p < 0.05.
Sensitivity and specificity were compared between the
two participating UAIs using the Fischer exact test. Cox
proportional hazard regression was used to calculate
unadjusted (uHR) and adjusted hazard (aHR) ratios to
explore predictors of mortality in the cohort of PLWH
with TB symptoms. The following confounding factors
were used for adjustment: age, sex, CD4 values, cART,
viral load, and WHO HIV stage. Data analyses were conducted using Stata, ver. 14 (Stata Corporation, College
Station, TX, USA).
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Results
Demographic and clinical characteristics of the PLWH
enrolled

PLWH flow charts for the diagnostic accuracy analysis
of the LAM-test vs. our composite referenced standard, and for the LAM-test performed in untreated vs.
α-mannosidase treated urine are depicted in Fig. 1.
Briefly, 292 out of 361 (80.9%) eligible PLWH had valid
results for Xpert, culture and both LAM-tests (untreated
vs. α-mannosidase treated urine) and thus, these were
used in the diagnostic accuracy analysis. PTB disease
was diagnosed in 59/292 (20.2%) PLWH with TB clinical symptom/radiological abnormality. Finally, there were
343 subjects with TB symptoms with information on
mortality outcomes that were used to study predictors of
death by Cox regression analysis.
Enrolled PLWH characteristics at baseline are shown
in Table 1. No differences were observed in age, sex and
BMI at both study sites, except for clinical symptoms of
weight loss and fever. Interestingly, Site 2 had higher proportion of second line cART regimens (65.3% vs. 10.6%)
and higher mortality risk (27.34% vs. 11.2%) with p values < 0.001 when compared to Site 1.
Diagnostic accuracy of the LAM‑test vs. the composite gold
standard by Site and CD4 values

We first determined the diagnostic accuracy analysis of
the LAM-test compared to the defined composite referenced standard. Overall, LAM test sensitivity was of
56.1 with 95% CI (43.3–68.3), and 62.2% with 95% CI
(46.5–76.2) in PLWH with CD4 T cell values < 200 cells/
µl. There were no differences in the LAM-test sensitivity
neither by UIA/Sites nor by CD4 T cell values.
Sensitivity and specificity comparison analysis of LAM‑test
in untreated vs. α‑mannosidase treated urine using
the composite reference standard stratified by CD4 T cell
values and Site

We further determined the sensitivity and specificity of
the LAM-test in α-mannosidase treated vs. untreated
urine when compared to the defined gold standard
composite. Results were stratified by Site and CD4 T
cell values (Table 2). No differences were observed in
the performance of the LAM-test with and without
α-mannosidase treatment of urine, neither when stratified by Site nor by CD4 values. There were 3 PLWH that
had a positive LAM-test result only when their urine was
α-mannosidase treated. Only 1 out of these 3 PLWH also
had a positive culture. Conversely, there were 5 PLWH
that their LAM-test result converted from a positive to
a negative when their urine was α-mannosidase treated.
Only 1 out of these 5 PLWH also had a confirmed TB
positive culture, the others presented negative cultures.
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Table 1 Characteristics at baseline registration of PLWH enroled by Site
Variable

Age

Median (IQR)

Sex

Sitea1, n = 266

nc

%d

nc

264

36 (28–51)

95

266
Male

28.46

0.831
0.229

22.11
32

3.27

No
BMIf

36 (31–44)
77.89

245
Yes

p valueb

%d

95
71.54

Female
Diabetese

Sitea 2, n = 95

< 0.001
50.00

96.73

50.00

217

95
19.71 (17.34–22.40)

0.146
18.82 (16.60–21.50)

TB symptoms
Cough

264
Yes

Weight lost

71
72.24

265
Yes

Night sweating

91
48.11

Fever

95
48.11
79
39.54

CD4 values at base‑
line

247

Viral load (copies/ml)

241

NA
100

95
185.50 (89–398)

< 0.001
49 (19–121)

95
39 200 (861–173 000)

cART regimeng

0.002
66.32

263
Yes

NA
100

264
Yes

0.639
74.74

226

0.059
93 616 (6044–242 469)

95

< 0.001

1st line

89.38

34.74

2nd line

10.62

65.26

cART defaulters
Yes
Death

18.72
260

Yes

18.00

0.431

27.37

< 0.001

95
11.20

NA Not applied
a

Site = Site 1 includes UAI 1 = “Dr. Isaac Cohen Alcahé” UAI and Rodolfo Robles Hospital. Site 2 includes UAI 2 = “Dr. Carlos Rodolfo Mejía-Villatoro” UAI and Roosevelt
Hospital

b

Pearson’s Chi squared p values for categorical variables and Mann-Whitney median comparison p value for independent samples

c

Variable sample size

d

Data are number (%) or median (IQR)

e

Hba1c measurements in % above 6.15 were considered the threshold for diabetic patients

f

In kg/m2

g

1st line regimens are based on a-ABC in combination with 3TC and either EFV or NVP or LPV/RTV, or ABC in combination with AZT and either EFV or LPV/RTV, or ABC
in combination with TDF and EFV; b-AZT in combination with 3TC and either EFV, or NVP, or LPV/RTV or ABC; c-TDF in combination with FTC and either 3TC, or EFV, or
NVP, or LPV/RTV, or AZT and 3TC
2nd line regimens are based on: a-ABC in combination with AZT and LPV/RTV, or in combination with DDI plus EFV, or DDI plus NVP or DDI plus SQV/RTV, b-AZT in
combination with 3TC plus ATV, or ATV/RTV or ATV/SQV, or AZT in combination with DDI plus LPV/RTV, c-DDI in combination TDF and EFV, or DDI in combination with
3TC plus NVP, or EFV, or SQV/RTV, or LPV/RTV
3rd line regimens and regimens including RAL, DRV, MRV used due to genetic resistance are included in 2nd line regimens. AZT (azidovudine), FTC (emtricitabine), TDF
(tenofovir), NVP (nevirapine), ABC (abacabir), 3TC (lamivudine), LPV/RTV (lopinavir/ritonavir), EFV (efavirenz), ATV (atazanavir), RAL (raltegravir), DRV (darunavir), MRV
(maraviroc), DDI (didanosine)

TB incidence rates and mortality rates and risk factors

TB incidence and mortality rates in our cohort of
PLWH with TB clinical symptoms were calculated using

person-years (PYs). Overall, 59 PLWH were diagnosed
with TB by the LAM-test, and 53 of those died. TB incidence was of 21.4/100 PYs with 95% CI of (16.6–27.6) for
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365 subjects registered
2 subjects were HIV negative, and 2
subjects were duplicated

361 Eligible PLWH enrolled

292 PLWH participants with valid results for culture,
LAM test with and without – mannosidase treatment
of urine, and Xpert*
71 missing Cultures, 69 missing
GeneXpert, and 2 missing LAM tests

59 PLWH had a TB confirmed diagnosis with at least 1
positive culture or GeneXpert positive result**
* Including, bronchoalveolar lavage fluid, cerebrospinal fluid, feces, blood, peritoneal, pleural liquid, skin, neck and lymph node biopsy aspirate
** Composite gold standard was defined by either a culture or a GeneXpert positive result.
PLWH: People living with HIV.
*** There were 11 patients without a recorded death date and were excluded from the Cox regression analysis.

Fig. 1 Patient flowchart for analyses of LAM and α-mannosidase urine LAM-test sensitivity and specificity and for mortality predictors

a total period of follow up of 275.6 PYs with a median
time of follow up of 333 days and IQR (117–521). TB
risk was of 16.3% with 95% CI of (12.9–20.5). To determine the mortality rate, 11 PLWH were excluded from
analysis as their death dates were not reported; thus the
42 recorded deaths gave a mortality rate of 11.1/100 PYs
with 95% CI (8.2–15.0) for a total period of follow up of
378.0 PYs, with a median time of follow up of 410 days
and IQR (230–571). Moreover, 19/42 (45.2%) and 31/42
(73.8%) of our study participants died during the first 3
and 6 months, respectively, after enrolment. Mortality
risk (n = 53) was of 14.9% with 95% CI of (11.6–19.1).
Of the PLWH that died, 21/44 (47.7%) were taken second line cART, and 9/53 (17.0%) were not taken cART or
their cART status was unknown.
Risk factors as predictors of mortality with TB clinical
symptoms

Results evaluating risk factors, as predictors for mortality and mortality outcomes for the 343 PLWH enrolled
in this study, are shown in Table 3. After the follow up
period, participants with a positive LAM-test result
(with and without α-mannosidase treatment) had an
aHR of death of 2.0 (1.0–3.8) p value = 0.044 as compared to PLWH with a negative LAM-test result. Overall, PLWH taking second line cART treatment had an
aHR of death of 2.4 (1.1–5.0) p value = 0.023 compared

to PLWH taking first line cART. Interestingly, specific for
UAI 1, being female [aHR of 2.4 (1.41–5.4) p value = 0.03]
and having a BMI < 17 kg/m2 [aHR of 2.7 (1.1–6.9) p
value = 0.029] were also considered predictors of mortality. Kaplan–Meier survival estimates are presented in
Fig. 2.

Discussion
Currently, this is the first reported diagnostic accuracy
analysis of the urine LAM-test performed in Central
America in PLWH. It is also the first time that an innovative procedure using α-mannosidase pre-treatment of
urine was implemented in clinical settings to evaluate its
diagnosis accuracy [14]. Importantly, a positive LAMtest result confirmed mortality prediction in our PLWH
cohort with TB clinical symptoms as previously reported
[23–28].
Our published laboratory data indicate that
α-mannosidase treatment of LAM-spiked human urine
using purified LAM from different M. tuberculosis
strains, can increase tenfold the detection of LAM molecules in urine by the LAM-test [14]. Our field validation
analysis of the LAM-test performed in α-mannosidase
treated vs. untreated urine was run in two different clinical settings. On one hand, PLWH attending Site 1 used
less second line cART, had higher CD4 T cell numbers
and lower viral load values, and lower mortality rates

b

60 (44.3–74.3)

28/39
11/12

17/27

Fischer exact Chi square test was used in comparisons among UAI

73.3 (44.9–92.2)

53.3 (34.3–71.7)

62.2 (46.5–76.2)
78.6 (49.2–95.3)

54.8 (36–72.7)
1

1

1

p valueb

1

1

1

p valueb

90.3 (85.6–93.8)
58.8 (32.9–81.6)

92.8 (88.4–95.9)

7/11

88/102

95/113

Negative/N

87.5 (47.3–99.7)

88.9 (81–94.3)

88.8 (81.2–94.1)

Specificity (% (95% CI)

LAM after α-mannosidase
treatment of urine

10/14

194/218

204/232

Negative/N

Specificity (% (95% CI)

LAM after α-mannosidase
treatment of urine

Site = Site 1 includes UAI 1 = “Dr. Isaac Cohen Alcahé” UAI and Rodolfo Robles Hospital. Site 2 includes UAI 2 = “Dr. Carlos Rodolfo Mejía” UAI and Roosevelt Hospital

11/12

Site 2

a

27/39

16/27

Both Sitesa

Positive/N

Positive/N

78.6 (49.2–95.3)

Sensitivity (% (95% CI)

11/18

55.2 (42.6–67.4)
49.1 (35.1–63.2)

Sensitivity (% (95% CI)

Site1

CD4 values < 200

73.3 (44.9–92.2)

37/59
26/41
LAM alone

11/18

Site 2

52 (37.4–66.3)

LAM after α-mannosidase
treatment of urine

26/41

56.9 (44–69.2)

Positive/N

Positive/N

37/59

Sensitivity (% (95% CI)

LAM alone

Sensitivity (% (95% CI)

Site1

Both Sites

a

All CD4 values

LAM after α-mannosidase
treatment of urine

90.2 (85.5–93.7)
61.1 (35.7–82.7)

92.7 (88.3–95.9)

8/11

88/102

96/113

Negative/N

88.9 (51.8–99.7)

89.8 (82–95)

89.7 (82.3–94.8)

Specificity (% (95% CI)

LAM alone

11/14

191/218

202/232

Negative/N

Specificity (% (95% CI)

LAM alone

1

1

1

p valueb

1

0.944

0.946

p valueb

Table 2 Sensitivity and specificity comparisons of LAM test after α-mannosidase treatment of urine vs. LAM test by Site and CD4 values using a composite gold
standard
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Table 3 Adjusted (aHR) Cox Hazard ratios for predictors of mortality in 343 PLWH with TB symptoms by Site
Both Sitesa
aHR

Site 1a

Site 2a

p value

aHR

0.412

1.00 (0.12–8.43)

p value

aHR

p value

NA

NA

0.998

ref

Ageb
≤ 20

21–30

ref
2.42 (0.29–20.17)

ref

31–40

2.26(0.27–18.53)

0.448

0.63 (0.07–5.30)

0.673

1.01 (0.30–3.46)

0.983

41–50

2.33 (0.28–19.06)

0.43

1.08 (0.13–8.69)

0.943

0.71 (0.16–3.06)

0.643

51–60

2.72 (0.31–24.20)

0.368

0.23 (0.01–3.91)

0.307

2.20 (0.56–8.66)

0.257

>60

1.43 (0.13–15.66)

0.957

0.69 (0.07–6.32)

0.741

NA

NA

0.448

0.51 (0.14–1.87)

0.312

2.43 (1.09–5.43)

0.658

NA

NA

0.52 (0.07–4.32)

Sex
Men

ref

Women

1.31 (0.65–2.61)

ref

ref
0.03

Diabetesc
No

ref

Yes

0.67 (0.12–3.86)

ref

ref
0.543

BMId
≥ 17 kg/m2

< 17 kg/m2

ref
1.41 (0.72– 2.79)

ref

ref

0.317

0.58 (0.12–2.73)

0.023

6.79 (2.16–21.31)

0.044

1.08 (0.32–3.67)

0.495

2.77 (1.11–6.92)

0.001

0.93 (0.42–2.05)

0.897

2.10 (0.94–4.67)

0.029

ARTe
1st line

ref

2nd line

2.39 (1.12–5.07)

ref

ref
0.853

LAM
Negative

ref

Positive

1.98 (1.02–3.84)

ref

ref
0.069

NA Not applied due to sample size limitations
The following confounders were used for adjustment: Age, sex, CD4 values, cART, viral load values, and WHO HIV stage
a

Site = Site 1 includes UAI 1 = “Dr. Isaac Cohen Alcahé” UAI and Rodolfo Robles Hospital

Site 2 includes UAI 2 = “Dr. Carlos Rodolfo Mejía” UAI and Roosevelt Hospital

b

Age was used as a continuous variable in the multivariable Cox regression for “Dr. Carlos Rodolfo Mejía-Villatoro” UAI

c

Hba1c measurements in % above 6.15 were considered the threshold for diabetic patients

d

In kg/m2

e

1st and 2nd line regimens are shown in Table 1

compared to PLWH attending Site 2. Most of PLWH
attending Site 1 were recruited as ambulatory patients,
compared to a higher proportion of hospitalized patients
recruited in Site 2, which includes the largest HIV clinic
of the country located in Guatemala City. Differences in
baseline characteristics of PLWH in these two Sites might
explain some of the differences in diagnostic accuracy of
the LAM-test. However, the LAM-test when compared
to the composite reference gold standard performed
equally in both Sites, regardless of the severity of WHO
clinical stage, cART status, viral load, and CD4 T cell
numbers. In addition, recent analysis show similar HIV
cascades of care in both Site1 and Site 2 [29].
In this study, the LAM-test sensitivity in PLWH
with < 50 CD4 T cells/µl was similar to PLWH with < 200
CD4 T cells/µl. A recent meta-analyses [26] showed a
median pooled LAM-test sensitivity for TB diagnosis in

PLWH of 45% with 95% credible interval of (29 to 63%),
which is similar to our results in this study [(56.1% with
95% CI (43.3–68.3)] but with a smaller range of interval
overlaps.
Contrary to our study in the laboratory setting, where
α-mannosidase treatment of LAM spiked human urine
significantly increased the efficiency of the LAM-test
[14], we did not find any sensitivity and specificity differences comparing the LAM-test results in α-mannosidase
treated vs. untreated urine using our composite gold referenced standard. This could be explained by several factors, including the viability and storage conditions of the
α-mannosidase enzyme being used in the IAUs, as well as
the use of a twofold diluted urine in sodium bicarbonate
when performing the LAM-test in the α-mannosidase
treated urine. This was performed with the rationale behind that sodium bicarbonate impairs micelle
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Fig. 2 Kaplan–Meier survival estimates by LAM-test result

formation of LAM molecules in aqueous buffer [30, 31],
but at the same time, the tested urine was diluted twofold, which could affect the sensitivity of the LAM-test.
Another potential reason is the non-use of low-binding
protein tubes during the test, as well as inconsistency in
the incubation periods and temperature, showing in the
lab setting to be optimal at 37 °C for 15 min [32].
Conversely, LAM in the infected host could be metabolized prior reaching the urine and thus, different
epitopes could be exposed on LAM molecules making
the α-mannosidase treatment less relevant than in the
laboratory in vitro setting. However, in this regard ongoing studies show that this later possibility may not be
plausible, as mannose-monocapped LAM motifs maybe
detected in urine isolated from active TB patients [33].
Indeed, we found 3 PLWH that had an α-mannosidase
LAM-test positive result, which were negative without
this treatment. Of these, only 1 had a positive culture.
Interestingly, there were 5 PLWH that had a LAM-test
negative result only after α-mannosidase treatment, that
otherwise were positive by the LAM-test using untreated
urine. Of these, only 1 had a TB culture confirmed, indicating that α-mannosidase treatment of urine could
potentially help in reducing false positive LAM-test
results and detect true TB positives that otherwise could
be missed. This is the first time that a modification of the
LAM-test to increase its sensitivity is performed in real
hospital-based settings worldwide showing promising

results in its feasibility; however, further careful largescale implementation and comparison analyses are necessary to verify its true usefulness in the field, especially in
rural areas with limited TB diagnosis testing accessibility.
The impact of the current Coronavirus disease 2019
(COVID-19) pandemic on the number of new TB and
HIV cases is unknown. Thus, in the years to come,
improving TB diagnosis in PLWH is a key target to
achieve towards the End TB strategy by 2030 [34–36].
TB/HIV services integration is highly recommended to
improve TB and HIV treatment outcomes, as well as to
establish TB/HIV programmatic indicators for surveillance, and monitoring and evaluation purposes [37, 38].
In this regard, TB incidence and mortality rates in PLWH
with TB symptoms found in our PLWH cohort showed
that even in HIV clinics with a “One Stop service delivery
model” for TB and HIV care, TB incidence and mortality are still a serious concern. Our TB incidence results
of 17.9/100 PYs and 95% CI of (10.4–30.8) in PLWH
with < 100 CD4 T cells/µl, are similar to those of 25.5/100
PYs and 95% CI of (21.6–30.3) found in a PLWH cohort
with similar CD4 T cell values in South Africa [39].
Indeed, our TB incidence rates of 22.5/100 PYs with 95%
CI of (11.2–45.0) in PLWH with < 50 CD4 T cells/µl, are
far higher than those of 4.2/100 PYs with 95% CI (1.4–
12.7) found in a cohort of PLWH in Nigeria with similar
CD4 T cell values [40]. Several studies have emphasized
different factors behind high proportions of AIDS

García et al. AIDS Res Ther

(2020) 17:62

defining illnesses such as late presentation, TB diagnostic
delay, and attrition in PLWH [27]. Social forces are key
determinants in explaining TB morbidity and mortality
outcomes in the Central American region that need to be
further explored.
Our data also indicate that a positive LAM-test result
in PLWH with TB clinical symptoms predicts mortality
outcomes [aHR of 1.98 (1.0–3.8) p value = 0.044]. This
was previously suggested in recent sub-Saharan Africa
studies involving hospital inpatients [4, 41], as well as in
PLWH receiving treatment for HIV-associated active TB
in sub-Saharan Africa and Thailand [42, 43], and in newly
diagnosed PLWH screened for TB in South-Africa [44].

Limitations
This pilot study was originally focused as a feasibility
study and a proper sample size calculation is missing.
LAM-test results using two independent readers in diagnostic accuracy analysis of the composite gold standard
vs. the LAM-test (urine untreated vs. α-mannosidase
treated) were not properly recorded. Thus, Kappa concordance agreement studies were not performed. LAMtest after urine α-mannosidase treatment was performed
in twofold diluted urine in sodium bicarbonate in place
of being directly performed in undiluted urine. However,
LAM-test using α-mannosidase diluted samples performed equally to LAM-test alone with undiluted samples Finally, LAM-test band intensity was not properly
registered and thus, results were only ascertained as positive or negative using the LAM-tests grade 1 to 4 independently of the intensity of the band visualized, which
limited to know if α-mannosidase treatment, a part of
uncovering true positives, was able to allow better detection of LAM molecules in urine by the LAM-test, and
further correlate the bacterial burden (culture) with the
intensity of the LAM-test band (i.e., a direct correlation
between more bacteria producing more LAM molecules
resulting in a high intensity band).
Conclusions
In this study, α-mannosidase treatment of urine did
not significantly increase the LAM-test performance;
however, the performance of the LAM-test after
α-mannosidase treatment of urine needs to be carefully revaluated in the field at larger scale and proper
controls. This simple α-mannosidase treatment of
urine could increase the sensitivity of the LAM-test
(and other urine-based test such the new FujiLAM
[45]), when compared to untreated urine in field settings using large cohorts of HIV-uninfected and
PLWH clinically suspicious of active TB disease. In
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this regard, it will be important to evaluate in the field,
if α-mannosidase treatment of urine can certainly
increase the detection of LAM molecules and correlate
these results with bacterial burden. Finally, high rates
of TB incidence and mortality were found within established “One Stop” services, and a positive LAM-test
result could predict mortality in PLWH with TB disease
clinical symptoms.
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